Literature DB >> 8461049

Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase.

C L van der Wilt1, H M Pinedo, M de Jong, G J Peters.   

Abstract

A series of natural and unnatural stereoisomers of reduced folate coenzymes have been studied for their capacity to facilitate binding of 5-fluoro-2'-dUMP (FdUMP) to bacterial thymidylate synthase (TS). The natural cosubstrate for the enzyme, (6R)-5,10-methylene-tetrahydrofolate (CH2-H4-folate), was 4-fold more potent than the unnatural 6S-form in promoting FdUMP binding to TS, but in a racemic mixture the effect of the 6R-form was not affected by the 6S-form. FdUMP binding to TS was also stimulated by tetrahydrofolate and dihydrofolate (85% and 30% as compared to (6RS)-CH2-H4-folate, respectively), but not by the stereoisomers of 5-methyl-tetrahydrofolate and 5-formyl-tetrahydrofolate (leucovorin). These results suggest that folates, which are not a natural cosubstrate for TS, have an additional role in facilitating FdUMP binding to TS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461049     DOI: 10.1016/0006-2952(93)90267-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; M P Djavanmard; W Scheithauer; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

Review 2.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

3.  Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.

Authors:  Bengt Gustavsson; Göran Carlsson; Torbjörn Swartling; Göran Kurlberg; Kristoffer Derwinger; Hillevi Björkqvist; Elisabeth Odin; Fernando Gibson
Journal:  Invest New Drugs       Date:  2015-07-21       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.